tsn

MilliporeSigma to invest over € 300 million in new bioproduction site in Korea

 346
0 comment
Staff at TrialSite | Quality Journalism
Mar. 24, 2024, 8:00 p.m.

MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, announced an investment of more than €300 million into a new Bioprocessing Production Center in Daejeon, South Korea.

The new site is the largest investment by the company’s Life Science business sector in Asia-Pacific to date and is expected to create approximately 300 additional jobs by the end of 2028.

Quality journalism costs money to produce.

Free access provides up to 10 articles

Subscription options start at $5 per month 
which is less than a Starbucks coffee!

Peter Gabriel, MD
"Publishing on TrialSite helped me secure a $20m research grant for my work."
Jona Savinda
"TrialSiteNews is my daily read for what is happening in the industry."
Lucas Van Der Hoven
"Objective, unbiased reporting on the latest news in medical research. I trust TrialSiteNews to give it to me straight."
TrialSiteNews
159 W Broadway, Suite 200
Salt Lake City, UT 84101
© 2025 - Trial Site News